NOVEL ANTIFUNGAL SCREENS--EXPRESSION INHIBITORS

Information

  • Research Project
  • 2024583
  • ApplicationId
    2024583
  • Core Project Number
    R43GM056040
  • Full Project Number
    1R43GM056040-01
  • Serial Number
    56040
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/1997 - 27 years ago
  • Project End Date
    11/30/1997 - 27 years ago
  • Program Officer Name
  • Budget Start Date
    6/1/1997 - 27 years ago
  • Budget End Date
    11/30/1997 - 27 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/9/1997 - 27 years ago
Organizations

NOVEL ANTIFUNGAL SCREENS--EXPRESSION INHIBITORS

The fungal cell wall protects the organism against a hostile environment and relays signals for invasion and infection of a likely plant, animal, or human host. The cell wall of fungi is synthesized at each hyphal apex in a complex assembly sequence. The fungal wall affords a clear and discernible difference between fungi and their human hosts, providing an experimental target for antifungal antibiotics. In this Phase I SBIR application, we propose to develop two novel screens that target the expression of each of two genes essential for cell-wall assembly, (1,3)beta-glucan synthase and Neurospora crassa os-1 histidine kinase. We will accomplish this in three Specific Aims: 1. Specific Aim One: Develop a screen for inhibitors of expression of a gene essential for (1,3)beta-glucan synthase activity, the glucan synthase-1 gene. 2. Specific Aim Two: Develop a screen for inhibitors of expression of an osmosensor histidine kinase, the osmotic sensitive-1 gene. 3. Specific Aim Three: Screen natural samples on a pilot scale These assays will lead to the identification of novel antifungal compounds that inhibit essential steps in cell-wall biosynthesis. Such drugs are likely to be safe and effective human therapeutics. PROPOSED COMMERCIAL APPLICATION Over the last four years the market for antifungal drugs has been one of the fastest growing markets for the pharmaceutical industry; 25% annual growth with the market total for 1995 of $4.2 Billion and the market is expected to grow to over $6 Billion by the year 2000. These assays will lead to the discovery of novel antifungal compounds that have significant market potential.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG5
  • Study Section Name
  • Organization Name
    MYCOLOGICS, INC.
  • Organization Department
  • Organization DUNS
    190042098
  • Organization City
    AURORA
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    80045
  • Organization District
    UNITED STATES